Insilico Medicine Brings AI-Powered "ChatPandaGPT" to its Target Discovery Platform

Insilico MedicineInsilico Medicine, a clinical-stage generative artificial intelligence (AI)-powered drug discovery company, has integrated advanced AI chat functionality based on recent advances in large language models into its PandaOmics platform. The new feature, "ChatPandaGPT," enables researchers to have natural language conversations with the platform and efficiently navigate and analyze large datasets, facilitating the discovery of potential therapeutic targets and biomarkers in a more efficient manner. Insilico Medicine is the first biotech company to implement chat functionality using large language models into its AI drug discovery platform.

PandaOmics is an AI-driven target discovery platform developed by Insilico Medicine that applies deep learning models to identify therapeutic targets associated with a given disease through a combination of omics data analysis put in the context of prior information coming from publications, clinical trials, and grant applications. The algorithm optimizes for the best potential therapeutic targets by scoring results on factors such as novelty, confidence, commercial tractability, druggability, safety, and other key properties that drive target selection decisions.

In November 2022, Insilico Medicine released the addition of a transformer-based knowledge graph to PandaOmics. The neural network of special architecture, the so-called transformer, extracts the relevant information from the list of scientific publications and produces a visually appealing graph that links genes, diseases, chemical compounds, and biological processes. The knowledge graph offers insights into the molecular mechanisms of diseases and the biological activities of genes and compounds in the context of a disease. It also reveals the most promising drug targets and biomarkers.

The new chat functionality, based on large language models, has been integrated with the knowledge graph functionality of PandaOmics and offers a more efficient, accurate, and personalized way to access information on molecular biology, therapeutic target discovery, and pharmaceutical development.

ChatPandaGPT offers additional features over the base on the general-purpose chat models. It draws from a specialized knowledge base, enabling it to provide accurate and detailed information related to molecular biology, therapeutic target discovery, and pharmaceutical development. It uses both natural language processing and machine learning algorithms, allowing it to provide more personalized and relevant responses to users on the platform. ChatPandaGPT is available at all times and can process multiple queries simultaneously without becoming tired or making mistakes.

"Insilico Medicine is excited to integrate this cutting-edge chat functionality into our PandaOmics platform," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. "By enabling researchers to have natural language conversations with the platform, we’re making it easier to navigate complex data and identify potential therapeutic targets and biomarkers."

PandaOmics is known for its advanced knowledge graph analytics platform, which enables users to discover relationships and insights within complex data structures. By integrating the latest advances in large language models, users can explore data in an even more intuitive and efficient way.

"We're thrilled to integrate this advanced chat functionality into PandaOmics," said Frank Pun, PhD, head of the PandaOmics application scientists team. "This integration represents a significant step forward in our efforts to provide researchers with the tools they need to make important discoveries in the field of drug discovery."

The integration between ChatPandaGPT and PandaOmics is available now, allowing researchers to begin navigating and analyzing large datasets and make important discoveries more efficiently.

About Insilico Medicine

Insilico Medicine, a clinical-stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases, and aging-related diseases.

About PandaOmics

PandaOmics is a therapeutic target and biomarker discovery platform developed by Insilico Medicine that features advanced knowledge graph analytics and state-of-the-art chat functionality. The platform is designed to help researchers identify potential therapeutic targets and biomarkers in a more efficient and streamlined way. https://insilico.com/pandaomics

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...